WeVote
Log In

Bill

Bill

SB 477

NO PRIOR AUTHORIZATION FOR CERTAIN DRUGS

2025 Regular Session Introduced by Martin Hickey

The bill would ban prior authorization and step-therapy for a broad set of drugs, speeding access but raising state program costs.

action postponed indefinitely
#alcohol&drugs #health&healthfacilities
0
WeVote Research Nonpartisan
Bill Summary · SB 477

SB 477 — “No Prior Authorization for Certain Drugs” (Introduced Feb 19, 2025) — SUMMARY

Note: Several different bills numbered “SB 477” appear in various states and on other topics. This summary focuses on the SB 477 titled “No Prior Authorization for Certain Drugs” (sponsor: Sen. Hickey) as analyzed in the posted fiscal note. Current status: Action postponed indefinitely.

Purpose / Intent

The bill would restrict health plans and public programs from using prior authorization (PA) or step‑therapy requirements for an expanded set of prescription medications. The intent is to increase timely access to specified drug classes by eliminating administrative barriers that can delay initiation of therapy.

Key provisions

  • Prohibits requiring prior authorization or step therapy for medications used to:
    • Treat or prevent cholesterol disorders;
    • Prevent or treat autoimmune disorders, cancer, and substance use disorders (some of these categories were already protected under existing law);
    • Include glucagon‑like peptide‑1 (GLP‑1) agonists, glucose‑dependent insulinotropic polypeptide (GIP) agents, and related incretin drugs (collectively described as “GLP‑1s”).
  • Removes PA/step‑therapy as an access condition for those drug classes; the bill reportedly removes the PA medical‑necessity determination in one provision while retaining medical‑necessity language in the step‑therapy prohibition (per fiscal note observation).
  • No effective date specified in the text; absent an effective date, would take effect 90 days after adjournment (the fiscal note cites June 20, 2025, as a reference date).

Who would be affected

  • Public purchasers / payers: Medicaid (Human Services/Health Care Authority), State Health Benefit Plan (SHBP), Retiree Health Care Authority (RHCA), New Mexico Public School Insurance Authority (NMPSIA).
  • Public providers and university programs: University of New Mexico Health Sciences Center (UNM‑HSC) and UNM Care program.
  • Private insurers may be indirectly affected (e.g., premium impacts), though the fiscal note does not quantify private‑market premium changes.
  • Patients prescribed the specified medications (including older adults and those with chronic conditions) — greater access and fewer administrative delays.
  • Pharmacy benefit managers and plan administrators — reduced PA/appeal workload but potential loss of utilization management tools and rebate/negotiation leverage.

Fiscal and programmatic impact (per Legislative Finance Committee / agency estimates)

Estimated recurring cost increases (state + federal matching where applicable):
- New Mexico Medicaid (HCA): ~$292.1 million annually (general fund $82.8M + federal match $209.3M) — $584.2M over two years shown.
- State Health Benefit Plan (SHBP): ~$19.4M first year; ~$40.6M over two years.
- New Mexico Public School Insurance Authority (NMPSIA): ~$10.8M first year.
- Retiree Health Care Authority (RHCA): ~$2.1M first year.
- University of New Mexico HSC / UNM Care: potential multi‑million impacts (UNM estimates ~$11M annually for self‑insured plan; ~$12M annually possible in UNM Care depending on uptake scenarios).
- LFC three‑year recurring total (rounded): ~$703 million (document shows ~$702.8M over a multi‑year horizon).

The fiscal note attributes cost increases to higher drug spend (especially GLP‑1s), loss of savings from utilization management, reduced rebates, and administrative fee impacts.

Significant issues / risks

  • Potential conflict with federal Medicaid rules on medical necessity and utilization controls — the fiscal note flags possible federal compliance concerns.
  • Clinical uncertainty about broad, long‑term safety and effectiveness of GLP‑1s in some populations (noted by RHCA / UNM‑HSC): concerns about adverse effects (e.g., muscle loss) in older patients.
  • The bill reduces utilization management levers that payers use to control costs, raising budgetary exposure for state programs.
  • It may change insurer contracting dynamics (rebates, formulary negotiations).

Procedural / timeline notes

  • Introduced Feb 19, 2025.
  • No effective date specified in the draft; default statutory timing (90 days after adjournment) would apply if enacted.
  • Current status (as provided): Action postponed indefinitely — commonly indicates the measure is not advancing at this time.

If you want, I can:
- Produce a one‑page plain‑language explainer for patients and clinicians about how the bill would change access to GLP‑1s and other drugs; or
- Compare this bill’s text to existing state law on prior authorization exemptions.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.